Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 226

1.

Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD; Australian Ovarian Cancer Study Group., Campbell IG, Gorringe KL.

Genome Med. 2017 Jan 12;9(1):1. doi: 10.1186/s13073-016-0392-y. No abstract available.

2.

The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".

Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, Bowtell DD, Dawson SJ, Speed TP, Swanton C, Loi S.

PLoS Med. 2016 Dec 27;13(12):e1002204. doi: 10.1371/journal.pmed.1002204.

3.

Commentary on "Epithelial-to-Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer".

Beach JA, Bowtell DD.

Cancer Res. 2016 Dec 15;76(24):7075-7077. No abstract available.

PMID:
27979802
4.

A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ.

Cancer Res. 2017 Feb 15;77(4):971-981. doi: 10.1158/0008-5472.CAN-15-2906.

PMID:
27923830
5.

The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.

Dickson KA, Cole AJ, Gill AJ, Clarkson A, Gard GB, Chou A, Kennedy CJ, Henderson BR; Australian Ovarian Cancer Study (AOCS)., Fereday S, Traficante N, Alsop K, Bowtell DD, deFazio A, Clifton-Bligh R, Marsh DJ.

Hum Mol Genet. 2016 Oct 25. pii: ddw362. doi: 10.1093/hmg/ddw362. [Epub ahead of print]

PMID:
27798111
6.

Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker.

Christie EL, Dawson SJ, Bowtell DD.

Cancer Res. 2016 Oct 1;76(19):5590-5591. No abstract available.

PMID:
27698187
7.

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2016 Sep 23. doi: 10.1158/1078-0432.CCR-16-0620. [Epub ahead of print]

PMID:
27663592
8.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project.; Australian Ovarian Cancer Study Group (AOCS).; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)., Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. No abstract available.

PMID:
27617737
9.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB; GEMO Study Collaborators., Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S; EMBRACE., Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)., Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN; KConFab Investigators.; Australian Ovarian Cancer Study Group., Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger LF, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, Menon U, Mensenkamp AR, Milne RL, Montagna M, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, O'Malley D, Orlow I, Orr N, Osorio A, Park SK, Pearce CL, Pejovic T, Peterlongo P, Pfeiler G, Phelan CM, Poole EM, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Rhenius V, Rhiem K, Risch HA, Rodriguez G, Rossing MA, Rudolph A, Salvesen HB, Sangrajrang S, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Sellers TA, Seynaeve C, Shah M, Shen CY, Shu XO, Sieh W, Singer CF, Sinilnikova OM, Slager S, Song H, Soucy P, Southey MC, Stenmark-Askmalm M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatchou S, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, Toland AE, Tomlinson I, Torres D, Truong T, Tseng CC, Tung N, Tworoger SS, Vachon C, van den Ouweland AM, van Doorn HC, van Rensburg EJ, Van't Veer LJ, Vanderstichele A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel JN, Wentzensen N, Whittemore AS, Wildiers H, Winqvist R, Wu AH, Yannoukakos D, Yoon SY, Yu JC, Zheng W, Zheng Y, Khanna KK, Simard J, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF, Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA.

Nat Commun. 2016 Sep 7;7:12675. doi: 10.1038/ncomms12675.

10.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.

Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2.

PMID:
27575023
11.

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL; Australian Ovarian Cancer Study Group., Harnett PR, Bowtell DD, DeFazio A.

Gynecol Oncol. 2016 Sep;142(3):458-64. doi: 10.1016/j.ygyno.2016.06.023.

PMID:
27444035
12.

Long-term survival of patients with mismatch repair protein-deficient, high-stage ovarian clear cell carcinoma.

Stewart CJ, Bowtell DD, Doherty DA, Leung YC.

Histopathology. 2017 Jan;70(2):309-313. doi: 10.1111/his.13040.

PMID:
27442838
13.

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.

Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K; Australian Ovarian Cancer Study Group., Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M; Ovarian Cancer Association Consortium., Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ.

J Natl Cancer Inst. 2016 Jan 27;108(3). pii: djv347. doi: 10.1093/jnci/djv347.

PMID:
26823519
14.

Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.

Winham SJ, Pirie A, Chen YA, Larson MC, Fogarty ZC, Earp MA, Anton-Culver H, Bandera EV, Cramer D, Doherty JA, Goodman MT, Gronwald J, Karlan BY, Kjaer SK, Levine DA, Menon U, Ness RB, Pearce CL, Pejovic T, Rossing MA, Wentzensen N, Bean YT, Bisogna M, Brinton LA, Carney ME, Cunningham JM, Cybulski C, deFazio A, Dicks EM, Edwards RP, Gayther SA, Gentry-Maharaj A, Gore M, Iversen ES, Jensen A, Johnatty SE, Lester J, Lin HY, Lissowska J, Lubinski J, Menkiszak J, Modugno F, Moysich KB, Orlow I, Pike MC, Ramus SJ, Song H, Terry KL, Thompson PJ, Tyrer JP, van den Berg DJ, Vierkant RA, Vitonis AF, Walsh C, Wilkens LR, Wu AH, Yang H, Ziogas A, Berchuck A, Chenevix-Trench G, Schildkraut JM, Permuth-Wey J, Phelan CM, Pharoah PD, Fridley BL, Sellers TA, Goode EL; Australian Ovarian Cancer Study Group..

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):446-54. doi: 10.1158/1055-9965.EPI-15-0240.

15.

A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.

Hernandez L, Kim MK, Noonan AM, Sagher E, Kohlhammer H, Wright G, Lyle LT, Steeg PS, Anver M, Bowtell DD; Australian Ovarian Cancer Study Group 57., Annunziata CM.

Cell Death Discov. 2015 Dec 14;1:15053. doi: 10.1038/cddiscovery.2015.53.

16.

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW.

Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877.

17.

Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.

Sinha D, Chong L, George J, Schlüter H, Mönchgesang S, Mills S, Li J, Parish C, Bowtell D, Kaur P; Australian Ovarian Cancer Study Group..

Clin Cancer Res. 2016 Apr 1;22(7):1813-24. doi: 10.1158/1078-0432.CCR-15-1931.

PMID:
26589433
18.

High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq.

Kondrashova O, Love CJ, Lunke S, Hsu AL; Australian Ovarian Cancer Study (AOCS) Group., Waring PM, Taylor GR.

PLoS One. 2015 Nov 16;10(11):e0143006. doi: 10.1371/journal.pone.0143006.

19.

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD; Australian Ovarian Cancer Study Group., Gorringe KL, Campbell IG.

Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438.

20.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group., Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. No abstract available.

PMID:
26503049
Items per page

Supplemental Content

Loading ...
Support Center